| First Author | Yook Y | Year | 2024 |
| Journal | EMBO Rep | Volume | 25 |
| Issue | 3 | Pages | 1233-1255 |
| PubMed ID | 38413732 | Mgi Jnum | J:349309 |
| Mgi Id | MGI:7614197 | Doi | 10.1038/s44319-024-00090-0 |
| Citation | Yook Y, et al. (2024) Hyperfunction of post-synaptic density protein 95 promotes seizure response in early-stage abeta pathology. EMBO Rep 25(3):1233-1255 |
| abstractText | Accumulation of amyloid-beta (Abeta) can lead to the formation of aggregates that contribute to neurodegeneration in Alzheimer's disease (AD). Despite globally reduced neural activity during AD onset, recent studies have suggested that Abeta induces hyperexcitability and seizure-like activity during the early stages of the disease that ultimately exacerbate cognitive decline. However, the underlying mechanism is unknown. Here, we reveal an Abeta-induced elevation of postsynaptic density protein 95 (PSD-95) in cultured neurons in vitro and in an in vivo AD model using APP/PS1 mice at 8 weeks of age. Elevation of PSD-95 occurs as a result of reduced ubiquitination caused by Akt-dependent phosphorylation of E3 ubiquitin ligase murine-double-minute 2 (Mdm2). The elevation of PSD-95 is consistent with the facilitation of excitatory synapses and the surface expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors induced by Abeta. Inhibition of PSD-95 corrects these Abeta-induced synaptic defects and reduces seizure activity in APP/PS1 mice. Our results demonstrate a mechanism underlying elevated seizure activity during early-stage Abeta pathology and suggest that PSD-95 could be an early biomarker and novel therapeutic target for AD. |
